15
AUG
2014
Mike Tranfaglia, MD, FRAXA Chief Scientific Officer

Fragile X Clinical Trials: is the mGluR Theory still valid?

POSTED BY MICHAEL TRANFAGLIA MD Why have clinical trials failed?  Tolerance and Dose Range In my opinion, the Fragile X clinical trials of AFQ056 sponsored by Novartis failed...
06
AUG
2014

Fragile X Clinical Trials: Was Tolerance the Problem?

Further thoughts on our AFQ056 experience POSTED BY MICHAEL TRANFAGLIA MD The recent Fragile X clinical trials sponsored by Novartis ended with a rather negativ...
24
JUL
2014
Iryna Ethell

Fragile X Syndrome Treatment Target: MMP-9

A major article from the Ethell lab at UC Riverside has shown the therapeutic potential of drugs that inhibit the enzyme MMP-9. A nice lay description of the new pap...
26
JUN
2014
Dr. Mike Tranfaglia with son, Andy

Fragile X Clinical Trial: Novartis trial results are in, and they’re not pretty

AFQ056 Fragile X Clinical Trial showed Negative Results This year’s Gordon Conference just finished, and Novartis presented their results for the first time (though...
23
MAY
2014
USA Today logo

FRAXA Featured in USA Today: Disappointments aside, optimism for Fragile X drugs

On May 22, 2014, USA Today featured an article surrounding FRAXA’s optimism for continuing to seek effective treatments for Fragile X, despite negative results in...
28
APR
2014
Mike Tranfaglia, MD, FRAXA Chief Scientific Officer

FRAXA Science Update Teleconference: Latest news about Fragile X Clinical Trials

When 10:30 am Eastern Daylight Time on Wednesday April 30, 2014   Topics FRAXA Medical Director, Dr. Michael Tranfaglia will discuss the latest results from the Novartis...
24
APR
2014

Novartis Discontinues Development of mavoglurant (AFQ056) for Fragile X Syndrome

Novartis Clinical Trials in Fragile X Ended Novartis has announced that the company will be discontinuing its development program in Fragile X for its lead mGluR5 antagonist,...
01
APR
2014

Experimental Drug FRAX486 Reverses Schizophrenia In Mice

A new study shows that one of a class of compounds known as PAK inhibitors, appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell...
share this Email this to someoneShare on FacebookShare on LinkedInTweet about this on TwitterShare on Google+Pin on PinterestShare on StumbleUpon